尔肾康合激素治疗小儿肾病综合征对血、尿白介素-6的影响

Influences of treatment with Ershenkang combined with corticosteroid for nephrotic syndrome on interleukin6 of blood and urine

目的：探讨尔肾康合激素治疗小儿肾病综合征（ＮＳ）对血、尿白介素 ６（ＩＬ ６）的影响及ＩＬ ６ 的检测意义。方法：采用双抗体夹心酶联免疫吸附（ＥＬＩＳＡ）法测定３０ 例ＮＳ患儿治疗前后血、尿ＩＬ ６ 的含量，并与２４ 例正常儿童作对照分析。结果：ＮＳ患儿治疗前尿ＩＬ ６显著升高，与对照组比较有极显著差异（Ｐ＜ ０．０１）；治疗后有显著降低（Ｐ＜ ０．０５）；治疗前初治组与非初治组相比，尿ＩＬ ６ 呈显著低值（Ｐ＜ ０．０５）；治疗后反复组较无反复组呈显著高值（Ｐ＜ ０．０５）。３０ 例健康儿童中２４ 例与３０ 例肾病患儿治疗前后血ＩＬ ６ 比较无显著差异（Ｐ＞ ０．０５）。结论：尔肾康合激素能降低尿ＩＬ ６，尿ＩＬ ６与病情密切相关。

Objective:To investigate the influences of treatment with Ershenkang(ESK) combined with corticosteroid for nephrotic syndrome(NS) on interleukin6(IL6) of blood and urine and the significances to delect IL6.Methods:The concentrations of blood and urine IL6 were measured in 30 children patients with NS before and after therapy by means of ELISA method and compared with 24 normal children as control.Results:In children patients before therapy the levels of urine IL6 were significantly increased and in comparison to control group the difference was significant ( P <0 01).After therapy they were significantly decreased ( P <0 05).Before therapy in comparison between primary treated group and nonprimary treated group the difference of urine IL6 was significant ( P <0 05).After therapy in recurrence group it compared to in nonrecurrence group showed obvious high level ( P <0 05).Conclusions:ESK combined with corticosteroid is able to decrease the level of urine IL6 which is tight relationship with pathogenetic condition.